AHA GUIDELINES Bundle (free trial)

Hypertrophic Cardiomyopathy 2024

AHA GUIDELINES Apps brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1521559

Contents of this Issue

Navigation

Page 3 of 43

4 Key Points 8. Patients with HCM and persistent or paroxysmal atrial fibrillation have a sufficiently increased risk of stroke such that oral anticoagulation with direct-acting oral anticoagulants (or alternatively warfarin) should be considered the default treatment option irrespective of the CHA 2 DS 2 -VASc score. New tools to stratify risk for incident atrial fibrillation have been developed and may assist in determining the frequency of screening patients with ambulatory telemetry. Because rapid atrial fibrillation is often poorly tolerated in patients with HCM, maintenance of sinus rhythm and rate control are key treatment goals. 9. Exercise stress testing is particularly helpful in determining overall exercise tolerance and for latent exercise provoked left ventricular outflow tract obstruction. Because children may not describe symptoms readily, routine exercise testing can be particularly important for young patients. 10. Increasingly, data affirm that the beneficial effects of exercise on general health are extended to patients with HCM. Healthy recreational exercise (light [<3 metabolic equivalents], moderate [3–6 metabolic equivalents], and vigorous [>6 metabolic equivalents] intensity levels) has not been associated with increased risk of ventricular arrhythmia events in short-term studies. If patients pursue rigorous exercise training for the purpose of performance or competition, it is important to engage in a comprehensive discussion and seek input from expert HCM professionals regarding the potential risks and benefits, to develop an individualized training plan, and to establish a regular schedule for reevaluation. Top 10 Take-Home Messages (cont'd)

Articles in this issue

Archives of this issue

view archives of AHA GUIDELINES Bundle (free trial) - Hypertrophic Cardiomyopathy 2024